title: New-Onset Diabetes Mellitus Associated with Sirolimus Use in Renal Transplant Recipients.
abstract: New-onset diabetes after transplantation and impaired glucose tolerance are very common in renal transplant patients. New-onset diabetes after transplantation (NODAT) is associated with increased cardiovascular morbidity and mortality, reduced graft and patient survival. Several risk factors for NODAT have been identified: age, obesity, family history of diabetes mellitus and HCV infection. In addition, steroid and calcineurin inhibitors also contribute to the development of NODAT. Sirolimus causes immunosuppressive effects by inhibiting mammalian target of rapamycin (mTOR), and has well known side effects. The effects of sirolimus on glucose metabolism and contribution to NODAT development are not clearly known. In this report, we presented five RTX patients who developed NODAT under the treatment of sirolimus.
authors.affiliation: Department of Internal Medicine, Division of Nephrology, Akdeniz University School of Medicine, Antalya, Turkey.
authors.forename: Vural Taner
authors.initials: VT
authors.lastname: Yilmaz
authors.affiliation: Department of Internal Medicine, Division of Nephrology, Akdeniz University School of Medicine, Antalya, Turkey.
authors.forename: Huseyin
authors.initials: H
authors.lastname: Kocak
authors.affiliation: Department of General Surgery, Akdeniz University School of Medicine, Antalya, Turkey.
authors.forename: Ayhan
authors.initials: A
authors.lastname: Dinckan
authors.affiliation: Department of Internal Medicine, Division of Nephrology, Akdeniz University School of Medicine, Antalya, Turkey.
authors.forename: Ramazan
authors.initials: R
authors.lastname: Cetinkaya
keywords: Renal transplantation; diabetes mellitus; sirolimus